Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Bone Marker and Bone Density Responses to Dopamine Agonist Therapy in Hyperprolactinemic Males

No abstract is available for this paper.

• Publication year

  year unknown

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• MicroRNA‐127‐3p Inhibits In Vitro Osteogenesis and Dampens Trauma‐Induced Heterotopic Ossification In Vivo

  2025cites this paper
• Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment

  2024cites this paper
• Effect of Hyperprolactinemia on Bone Metabolism: Focusing on Osteopenia/Osteoporosis

  2024cites this paper
• Diagnosis and therapeutic approach to bone health in patients with hypopituitarism

  2024cites this paper
• Skeletal fragility in pituitary disease: how can we predict fracture risk?

  2024cites this paper
• Modern approach to bone comorbidity in prolactinoma

  2024cites this paper
• Impact of medical therapy for hormone-secreting Pituitary tumors on bone

  2024cites this paper
• Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors

  2022cites this paper
• A Meta-Analysis of Antipsychotic-Induced Hypo- and Hyperprolactinemia in Children and Adolescents

  2022cites this paper
• Bone microarchitecture impairment in prolactinoma patients assessed by HR-pQCT

  2022cites this paper
• Pituitary Adenomas: From Diagnosis to Therapeutics

  2021cites this paper
• The Relationship Between Bone and Reproductive Hormones Beyond Estrogens and Androgens

  2021influential citation
• Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas

  2021cites this paper
• Update on vertebral fractures in pituitary diseases: from research to clinical practice

  2021cites this paper
• Endocrinology of Bone and Growth Disorders

  2021cites this paper
• Osteoporosis and arthropathy in functioning pituitary tumors

  2021cites this paper
• Glucose Metabolism in Osteoblasts in Healthy and Pathophysiological Conditions

  2021cites this paper
• Impact of glucose-lowering medications on bone health in diabetes

  2020cites this paper
• A rational approach to the evaluation and management of patients with hyperprolactinemia

  2020cites this paper
• Hyperprolactinemia and bone

  2020cites this paper
• The epidemiology, diagnosis and treatment of Prolactinomas:The old and the new.

  2019cites this paper
• Hyperprolactinaemia

  2019cites this paper
• Identifying novel anti-osteoporosis leads with a chemotype-assembly approach.

  2019cites this paper
• Estimation of serum prolactin levels and determination of prevalence of hyperprolactinemia in newly diagnosed cases of subclinical hypothyroidism

  2018cites this paper
• Dopamine receptor expression on primary osteoblasts and bone marrow mesenchymal stem cells of rats

  2018cites this paper
• Hypothalamic-Pituitary Diseases

  2018cites this paper
• Hyperprolactinemia: A Systematic Review of Diagnosis and Management

  2018cites this paper
• Pituitary Diseases and Bone

  2018cites this paper
• Neuroendocrinology of Bone Metabolism

  2018cites this paper
• Prolactinoma and Bone

  2018cites this paper
• Dijagnostičke i terapijske mogućnosti liječenja prolaktinskih tumora

  2018cites this paper
• Hyperprolactinaemia: A guide for psychiatrists

  2017cites this paper
• Cabergoline Tapering Is Almost Always Successful in Patients With Macroprolactinomas

  2017cites this paper
• Prolactinoma through the female life cycle

  2017cites this paper
• Chapter 16 – Prolactinoma

  2017cites this paper
• The safety of treatments for prolactinomas

  2016cites this paper
• Osteoporosis in pituitary diseases: lessons for the clinic

  2015influential citation
• Pituitary diseases and bone.

  2015cites this paper
• Bone and Joint Disorders in Acromegaly

  2015cites this paper
• Hyperprolactinémie

  2015cites this paper
• Efectos adversos de antipsicóticos atípicos, diferencias según sexo

  2014cites this paper
• Pituitary Disorders and Osteoporosis

  2014cites this paper
• Capítulo 17 – Hiperprolactinemia y osteoporosis

  2014cites this paper
• Prolaktin und HyperprolaktinämieStellungnahme der Deutschen Gesellschaft für Gynäkologische Endokrinologie und Fortpflanzungsmedizin (DGGEF) e.V.

  2013cites this paper
• Uma abordagem dos Prolactinomas, à luz das evidências científicas atuais

  2012cites this paper
• Treatment of hyperprolactinemia: a systematic review and meta-analysis

  2012cites this paper
• Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis

  2012cites this paper
• The risk of osteopenia in premenopausal women with various sellar tumors

  2012cites this paper
• Risk of osteoporosis and fracture incidence in patients on antipsychotic medication

  2011cites this paper
• Patients with hyperprolactinemia clinical and epidemiological perspectives

  2011cites this paper
• Vertebral fractures in males with prolactinoma

  2011cites this paper
• Treatment for prolactinomas and hyperprolactinaemia: a lifetime approach

  2011cites this paper
• Evaluation of bone mineral density in hyperprolactinemic patients treated with dopamine agonists

  2011influential citation
• Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis

  2011cites this paper
• Bone Remodeling, Bone Mass and Weight Gain in Patients with Stabilized Schizophrenia in Real-Life Conditions Treated with Long-Acting Injectable Risperidone

  2011cites this paper
• Ostéoarthropathies d'origine endocrinienne

  2011cites this paper
• Medical treatment of prolactinomas

  2011cites this paper
• High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas

  2011cites this paper
• A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys.

  2010cites this paper
• Prolactinomas in children and adolescents.

  2010cites this paper
• Vitex agnus castus as prophylaxis for osteopenia after orchidectomy in rats compared with estradiol and testosterone supplementation

  2009cites this paper
• Antipsychotika und Hyperprolaktinämie: Pathophysiologie, klinische Bedeutung, Abklärung und Therapie

  2009cites this paper
• Bone density and turnover in young adult patients with growth hormone deficiency after 2-year growth hormone replacement according with gender

  2008cites this paper
• Hyperprolactinemia and prolactinomas.

  2008cites this paper
• The role of cyclase activating (CAP) and cyclase inhibiting (CIP) parathormone fractions in the assessment of bone metabolism disturbances in women with hyperprolactinemia of various origin.

  2008cites this paper
• The effects of hyperprolactinemia on bone and fat

  2008influential citation
• Bone mineral density and bone turnover in hyperprolactinaemia of various origins.

  2007influential citation
• Short-term prolactin administration causes expressible galactorrhea but does not affect bone turnover: pilot data for a new lactation agent

  2007cites this paper
• Bone density in women with prolactinoma treated with dopamine agonists

  2007influential citation
• Technology Insight: measuring prolactin in clinical samples

  2007cites this paper
• Relation between Bone Mass and Catecholamines in the General Population

  2007cites this paper
• Drug Insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women

  2006cites this paper
• Current treatment issues in female hyperprolactinaemia.

  2006cites this paper
• MACROPROLACTINEMIA NUMA COORTE DE MULHERES COM HIPERPROLACTINEMIA: ASSOCIAÇÕES COM VARIÁVEIS CLÍNICAS, HORMONAIS E EXAMES DE IMAGEM DA HIPÓFISE

  2006cites this paper
• Ostéopathies endocriniennes (en dehors de l'hyperparathyroïdie)

  2006cites this paper
• Advances in the treatment of prolactinomas.

  2006cites this paper
• Prolactinomas e densidade mineral óssea em homens

  2005cites this paper
• revisão Prolactinomas e Densidade Mineral Óssea em Homens

  2005cites this paper
• Hiperprolaktinemi : Taný ve Tedavisi HYPERPROLACTINEMIA : DIAGNOSIS AND TREATMENT

  2005cites this paper
• Low bone density with the use of valproate.

  2005cites this paper
• Prevalence of osteopenia in men with prolactinoma

  2005cites this paper
• Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.

  2004cites this paper
• The Effect of Atypical Antipsychotic Agents on Prolactin Levels in Children and Adolescents

  2004cites this paper
• Biochemical and Molecular Actions of Nutrients Maternal Zinc Deficiency Raises Plasma Prolactin Levels in Lactating Rats

  2004cites this paper
• From Galactorrhea to Osteopenia: Rethinking Serotonin–Prolactin Interactions

  2004cites this paper
• Contemporary management of prolactinomas.

  2004cites this paper
• Aspectos clínicos e terapêuticos de prolactinomas em homens

  2003cites this paper
• This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the author's clinical recommendations. Prolactinoma

  2003cites this paper
• Diagnosis and management of hyperprolactinemia.

  2003cites this paper
• Association of a polymorphism of the dopamine receptor D4 gene with bone mineral density in Japanese men

  2003cites this paper
• 57-jähriger Patient mit Doppelbildern und Kopfschmerzen

  2003cites this paper
• Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study

  2003cites this paper
• Hyperprolactinemia in men

  2003cites this paper
• Pharmacological effects of Cimicifuga racemosa.

  2003cites this paper
• Fracture risk is increased in patients with GH deficiency or untreated prolactinomas – a case‐control study

  2002cites this paper
• Secondary causes of osteoporosis.

  2002cites this paper
• Dopamine receptor agonists for treating prolactinomas

  2002cites this paper
• Severe impairment of bone mass and turnover in Cushing’s disease: comparison between childhood‐onset and adulthood‐onset disease

  2002cites this paper
• Osteopatías endocrinas (exceptuando el hiperparatiroidismo)

  2001cites this paper
• Long‐term follow‐up of 246 hyperprolactinemic patients

  2001cites this paper